Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Gliosarcoma × ficlatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Lymphoid Interstitial Pneumonia 1 Lip Neoplasms 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Carcinoma, Squamous Cell 1 Carcinoma 1

Interventions

Temozolomide 80 Radiotherapy 47 Bevacizumab 29 Irinotecan 18 Radiation 15 Erlotinib Hydrochloride 14 Carmustine 13 Magnetic Resonance Spectroscopy 12 O(6)-benzylguanine 10 Chemotherapy, Adjuvant 10 sargramostim 8 Thalidomide 8 Imatinib Mesylate 8 Carboplatin 8 Gene Expression Profiling 6 Filgrastim 6 Drug Therapy 6 Surgical Procedures, Operative 5 Radiotherapy, Intensity-Modulated 5 Hydroxyurea 5 Gefitinib 5 pembrolizumab 4 aldesleukin 4 Topotecan 4 Immunohistochemistry 4 Etoposide 4 Dasatinib 4 Celecoxib 4 Biopsy 4 Aminolevulinic Acid 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡